Telehealth & Medicine Today

Telehealth and Medicine Today (TMT) is a leading international peer review journal that examines the value of telehealth and clinical automation from medical, technical, policy, economic and strategic perspectives



Telehealth and Medicine Today (TMT)


About & Scope


Telehealth and Medicine Today (TMT) is a leading international peer review journal that examines the value of telehealth and clinical automation  from medical, technical, policy, economic and strategic perspectives. Multidisciplinary stakeholders converge to address medical, technical, business and societal aspects of this growing health technology sector. The journal assists building knowledge and consensus to appropriately deploy and scale delivery safe and secure services to achieve sustainable outcomes for affordable, accessible, and quality care for health consumers around the globe, implementing pragmatic approaches to issues such as interoperability, quality and safety of evolving technologies, business processes, and economic systems driving remote care in a value based system. A world-class review board endeavors to offer rapid peer-review (14 days per review round), and includes constructive commentary to strengthen work. TMT is published quarterly. The journal registers original research article provenance on the blockchain for authors to have a permanent and immutable public record of their work to share with the scientific research community at TMT+ARTiFACTS RESEARCH PORTAL. 

The Telehealth and Medicine Today audience includes leadership from enterprise, hospitals and medical research centers, payer organizations including researchers, medical directors, IT/IS, healthcare providers, universities, consultants, entrepreneurs/startups, biopharma/device/pharmacy, NGO, government, and policy.



TMT Editorial Focus


Manuscripts of interest will present local and global innovations fostering ecosystem efficiencies in virtual care, telecare, and telehealth utilizing evidence-based outcomes for:

New Business Models, Provider strategies, incentive models, future society transformation strategies, hardware, software and technology selection, financial Impact to health systems and patient out-of-pocket cost, scalability, sustainability.

Technology: Artificial intelligence, machine learning, robotics, voice interface tech, augmented reality, identity management, security, data management, interoperability, standards, scalability, business continuity, consumer technology adoption, patient privacy, conversational AI, data reporting accuracy, embedded technologies, sensors, diagnostics, Chabots, augmented reality, virtual reality, self-guided care, connectivity 

USE CASES: use case discovery frameworks, use case roadmaps, key learnings from successful and unsuccessful experiences

Legal and Regulatory: Reimbursement, reduced hospital readmissions, interoperability, mobile health, devices, EMR, health and wellness consumer protection, health policy, patient privacy (GDPR and HIPAA)

HEALTH IT: Electronic health records (EHR), health information exchange (HIE), interoperability, data analytics, claim adjudication, clinical trials, medical devices, Internet of Things (IoT), wearables, sensors, smart health cities and medically fit homes

Home Care: Long-term care, care giver strategies, remote health, smart cities, sensors, workforce 

Drug Discovery: Protocol development, clinical study management, devices, sensors, data aggregation,

Security and Governance: Oversight, workflow, staffing solutions, recruitment, scaling, monitoring, and maintaining of security systems

Trending Specialties: Population health, chronic condition management, behavioral health, Tele-dermatology, Tele-radiology, Tele-pathology, smart cities and ecosystems for mid-life and beyond 

USER EXPERIENCE: market and user segmentation, generational demographics, consumerization of healthcare, behavioral considerations, user centered design, adoption drivers and barriers, Return-on-Adoption

EDUCATION: Training tools & tips - the fundamentals, innovation management, managing digital transformation, future workforce, medical education 





Authors around the globe are invited to submit original papers under the following categories:

  • Proof of Concept
  • Use Cases, Pilots
  • Methodologies
  • Production, Deployment
  • Technical Report (1500 words)
  • Original Clinical Research
  • Original Market Research
  • Narrative/Systematic Reviews/Meta-Analysis
  • Opinions, Perspectives, and Commentary on a current trend or issue impacting the sector
  • Training and Tool Kits

In addiion, TMT publishes a BLOG, where authors can share experiences and reflections including commentary, discussion and debate on any aspect of healthcare, policy, and technology around the globe. The submission should be approximately1000 words.



Time Stamped Ledger of Record for Researchers 

TMT is pleased to offer the first life science research portal for authors and global communities. The portal registers each original research article’s provenance on the blockchain for every author to create a permanent and immutable public record of their work on the blockchain for the scientific community.
The TMT+ARTiFACTS portal provides custom dashboards so authors and research teams can:

  1. Transact smart contracts on the blockchain to secure the provenance of their research files and receive citations in real time
  2. Control access to their research materials
  3. Synchronize with their ORCID ID’s and works and many other capabilities and features




TMT follows guidelines for authorship recommended by the ICMJE. Please click this link to review and determine authorship criteria for your submission. Authors must meet all four criteria to be listed as authors. We ask you to familiarize yourself with the recommended guidelines. Thank you.

Publishing Schedule

TMT is published quarterly to reflect a dynamic marketplace to ensure accurate reflection of developments, trends, and the most current knowledge available, while providing a forum for developing shared work and consensus. 2020 issues will be published in January, April, July and November. 

DEADLINE for manuscript submissions:  December 1, March 1, June 1, and October 1. 

All TMT articles and content are open access for readers. There is no charge. 



TMT Audience

The Telehealth and Medicine Today audience includes leadership from enterprise, hospitals and medical research centers, payer organizations including researchers, medical directors, IT/IS, healthcare providers, universities, consultants, entrepreneurs/startups, biopharma/device/pharmacy, NGO, government, and policy.



Governing Body

TMT editorial leadership is comprised of world-renowned experts bringing depth and breadth of knowledge, and curiosity, to the journal. For a complete list of editorial board members and financial disclosures, please click this link. 

Lyle Berkowitz, MD, FACP, FHIMSS, CEO of Back9 Healthcare Consulting, USA

Focus area: Primary Care, Physician Satisfaction and Process innovation

Amar Gupta, PhD, MIT’s Institute of Medical Engineering and Science (IMES), USA

Focus area: Technology, Policy & Regulation

John D. Halamka, MD, MS, President, Mayo Clinic Platform, USA

Focus area: Emergency and Hospital Medicine, Interoperability and Device Innovation

Please send inquireis to 



Fees and Publishing Model

TMT’s Article Processing Charge (APC) is $350.00 USD, for manuscripts. 

There is NO APC for students currently enrolled at an academic institution or BLOG posts.

What does the article-processing charge (APC) cover?
 Costs are involved in every stage of the publication process, including software, hosting, copy editing, production, proofs, archiving on dedicated servers, time stamping article provenance on the distributed ledger, and providing custom dashboards to authors.  We ask authors to pay an APC if their original research article is accepted for publication. Once published, authors can immediately post their article on non-commercial web sites, institutional repositories, or other free public servers. 



Waiver policy

Submit a request to the publisher if your manuscript is accepted at

Archiving and Scholarly PracticesTMT uses LOCKSS preservation, Portico, and CrossRef. We adhere to ICMJE, COPE, and WAME guidelines and practices. 

IndexingTMT is indexed in Unpaywall, Google Scholar and Public Knowledge Project metadata harvester.

Revenue sources:  TMT revenue consists of advertising support for the journal, reprints, special editions, supplements, summits, roundtables, and custom projects.  The portfolio also curates the annual Converge2Xcelerate (#ConV2X) conference. Under no circumstance does commercial support impact the editorial decisions for journal manuscript review or acceptance.

Owned and managed byPartners in Digital Health (PDH)

Partners in Digital Health (PDH), is a forward reaching communications company publishing the peer review journals Blockchain in Healthcare Today and Telehealth and Medicine Today, producer of the companion ConVerge2Xcelerate (#ConV2X) conference series, and Innovation Ignition Pitch Competition. The portfolio converges leading academics, pragmatic innovators, and practitioners around the globe to assist in the acceleration of healthcare transformation, and better outcomes for health consumers presenting evidence based fact. PDH continuously pushes the boundaries of technology innovation in scholarly publication and ecosystem practices to bring trust, transparency, and truth to its audience.

Those with an interest in submitting a manuscript or obtaining further information are encouraged to do so. Send inquiries to the Managing Editor, John Russo, PharmD, at  or the  owner and Publisher, Tory Cenaj, at



Journal Information


Journal Policies and Operations Procedures:

  • Peer review
  • Rejections
  • Reviewer’s Check List
  • Editorial decisions
  • Appeals
  • Proofs and reprints
  • Reviewing Feature Articles and Opinions
  • Unlabeled use
  • Content validation
  • Patient consent
  • Statistical analysis
  • Publication ethics
  • Data sharing and reproducibility
  • Ethical Publishing Practices
  • Plagiarism
  • Misconduct



Peer Review  

Becoming a reviewer

Editors are selected either by self-nomination, or by nominations that are made from the Editors-in-Chief and Editorial Board whereby reviews of letters, curriculum vitaes and interviews are conducted with the candidate and/or colleagues and experts in the field are conducted.  TMT seeks the experts of the highest caliber and passion for the field, and prefers candidates that possess knowledge of academic journal workflow and familiarity with the peer review process.

To become a member of the TMT Peer Review board, please send a letter to the editor, with your CV attached, to


Peer review policy

All submissions are first reviewed to determine if plagiarized content is contained by the managing editor. If so, submissions are returned to the author with comment(s), or rejected outright. The focus area Editor-in-Chief reviews and approves all submissions to determine whether the submission is routed for peer review after the plagiarism check. Once a submission has been accepted for peer review, expert reviewers are asked to assess the merits of the work and provide feedback to communicate to the corresponding author should revisions be required, or accept the paper.

Two to three peer reviewers are assigned to each paper. Two peer reviewers must accept the paper for publication, or provide commentary for revisions for a resubmission. If we do not possess board expertise to conduct a review, we will ask the author for suggestions for expert reviewers, and invite them to act as expert guest reviewer for the submission. This will likely delay the review process. The managing editor will inform authors to expect delays if inviting a guest reviewer is required.

TMT strives to ensure peer review is fair, unbiased and timely. All manuscripts and associated material submitted to TMT remain confidential while under review. TMT endeavors to review submission within 14 business days.

TMT Peer Review is anonymous and double blind. All manuscripts submitted for publication undergo peer review including those submitted by editorial board members, regular columns, features and op/eds, and themed issues. Editor and publisher letters, and Prediction articles do not undergo peer review.



Submissions are rejected most often due to poor formatting, lack of substantiating claims, plagiarism, and citation errors. Submissions that rehash general information already in the public domain are rejected. Previously published materials and white papers are not acceptable unless COPE guidelines are strictly followed. Contact the managing editor with questions at


Reviewer’s check list

Reviewers are selected based on expertise. TMT reviewers are expected to recuse themselves if they have a potential competing interest, including the following:

  • Prior or current collaborations with the author(s) if known
  • Reviewer is a direct competitor
  • Reviewer may have a known history of antipathy with the author(s)
  • Reviewer may profit financially from the work

Reviewers will not accept a peer review invitation should a conflict exist and will decline the review invitation whereby the managing editor will invite an alternate reviewer.


Writing the review

The purpose of the review is to provide the focus area Editor-in-Chief and managing editor with expert opinion regarding the quality of the manuscript, and supply authors with clear and concise feedback on how to improve papers so that they may be acceptable for publication.

All comments are communicated to the author. Reviewers are asked to consider the following when reviewing a submission:

  • What are the main claims of the paper and how important are they?
  • Are these claims novel? If not, specify papers that weaken the claims to the originality of this one.
  • Are claims properly placed in the context of previous literature?
  • Do results support claims? If not, what other evidence is required?
  • Would other experiments or information improve the paper? Would it significantly improve the paper to do more work?
  • Is the paper outstanding in its discipline? What makes it so? If not, why?
  • Who would find this paper of interest? Why?
  • Does it suit the journal’s audience?
  • If the paper is unsuitable for publication in its present form, is there potential to encourage the author to resubmit a revised version?

Reviewers are asked to be matter of fact, clear and concise.

Will authors know who is reviewing their manuscript?

Reviewers’ identities are anonymous.

Can authors exclude Editorial Board Reviewers or Independent Reviewers?

Yes, authors can request to exclude a specific reviewer from reviewing their manuscript as long as TMT peer review process remains  intact and a thorough assessment of the article is given. A decision letter is sent to the author when all reviews are received and considered.



The Managing Editor and Reviewers assess revised manuscripts. Manuscripts that undergo major revision are re-reviewed. There is no guarantee of acceptance after major revision. Revisions are generally requested if a manuscript is considered appropriate. Minor revisions are usually requested as a final step before acceptance.


Editorial decisions

Should reviewers reject the submission or resubmission, the managing editor will alert the Editors-in-Chief  to determine whether the submission warrants publication and benefits the sector. The Editors-in-Chief and managing editor will, together, make a decision based on the reviewers' comments, and may contact the reveiwers to discuss in more depth. 



To appeal a decision, you can contact the Managing Editor and explain your reason(s) for the appeal. When a paper has been revised in response to the review, or when authors appeal against a decision, we ask reviewers to provide follow-up commentary.

All appeals are discussed with the Editors-in-Chief and reviewers assigned to the submission.  In the case of disagreement, TMT may seek external advice on the appeal, but it is most likely the final decision will be left to the Editors-in-Chief.

Only one appeal will be considered. The Editors-in Chief decision will be final.


Proofs and reprints

Corresponding authors of accepted submissions are sent galley proofs with final queries for production.. Corrections should be relayed to the Managing Editor as soon as possible to facilitate publication. 

Reprints may be ordered once published with a request send to the publisher at


Reviewing Feature article and Opinion submissions

TMT Peer reviewers are asked to review these submissions considering the following:

  • Is the article relevant and of interest to an international audience?
  • Does it address a global and topical subject? Will it be relevant across demographic populations?
  • Is the article well written, clear, and easy for a non-specialist?
  • Do you think the article will impact clinicians, researchers, health policymakers, or the public? Will it be widely read, disseminated, or cited? Could it improve public and/or global health? Will media outlets find it news worthy?
  • Is the article accurate? Are claims evidence-based?
  • Has the author missed anything important?
  • Does the article contain new information warranting publication? Does it take a discussion or debate into a new direction? Does it challenge current legacies?
  • Is it written in a scholarly format? Is it referenced?
  • If tables and figures are included, do they help the reader, or hinder topic and focus? How can they be improved?

Note: TMT BLOG is not peer reviewed. The managing editor reviews submissions and determines topical audience relevance for publication. 



For feature/opinion articles, TMT editorial judgment for readability and engagement is decidedly important. An appeal is less likely to overturn a TMT editorial decision. You are welcome to submit a detailed rebuttal letter. Only one appeal will be considered. The Editors-in Chief decision will be final.


Disclosure of Unlabeled Use

Articles published by TMT may contain information and discussions of published and/or investigational uses of devices and agents that are not indicated by the Food and Drug Administrations (FDA).  Partners in Digital Health, publisher of TMT, does not recommend the use of any device or agent outside lawful and labeled indications.


Policy on content validation

All the recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of animals and patients

All scientific research referred to, reported, or used in a patient care recommendation must conform to accepted standards of experimental design, protocols, data collection and analysis


Patient consent

As recommended by the International Committee of Medical Journal Editors ( Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, 01/02/2018.  Available from:, authors will ensure the guidelines below are followed. TMT has quoted the text below from ICMJE Protection of Research Participants for authors to know and follow:

"Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients’ names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published.

Identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve, however, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is usually inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. When informed consent has been obtained it should be indicated in the submitted article."


Statistical analyses

Ensure the methodology has been accurately described for statistical analysis. Include details and access to original data to verify results. Provide confidence levels, and define terms and symbols.  Include software used. In comparative studies, power calculations are usually required. In research manuscripts, requiring complex statistics, the advice of an expert statistician should be sought at the design/implementation stage of the study. It is appropriate to include statisticians as co-authors. Should you have further questions, please contact the managing editor.


Publication Ethics

Data sharing and reproducibility

TMT time stamps all articles, meta data and supplementary research data submitted on the distributed ledger in partnership with and provides authors with a custom dashboard to independently manage to add additional research. TMT encourages all authors around the globe to openly share data for purposes of reproducibility. TMT also asks authors and readers to share articles to encourage broadening the sector’s knowledge base.

TMT suggests authors include a data sharing statement when making a submission explaining:

What additional unpublished data from the study is available

Who can access the data and how can it be obtained

In addition, TMT encourages uploading your code at Code Ocean, a cloud-based computational reproducibility platform. We encourage you to include your code with your manuscript submission for peer review, as well as publish this code to share with all upon article acceptance.

In addition, Dryad has declared its willingness to accept medical datasets.



The copyright owner retains all rights to IP, patents, and trademarks for their work(s). All rights to the owner of IP, patents and trademarks are retained by the owner. Sharing articles for professional and personal use is strongly encouraged.


Post publication discussion and corrections

TMT encourages collegiate discourse and transparency to assist the expansion of the body of knowledge and understanding within and beyond the sector. This can only be achieved with the highest ethical principles for education and science.


Ethical Publishing Practices

Submitted manuscripts should be exclusively submitted to TMT, with the understanding they have not been published elsewhere, in any form, and will not be submitted elsewhere, unless declined by TMT. Authors are responsible for all statements made in the article and references cited.


Plagiarism detection

TMT is a member CrossRef and Similarity Check, iThenticate. We use the Similarity Check plagiarism tool to verify originality of content. TMT screen all manuscripts upon submission. If the managing editor identifies plagiarized content, the submission will be returned with comment(s), or rejected outright.

TMT strives to abide by the guidelines and standards prescribed by Committee on Publication Ethics (COPE), its Code of Conduct, and its Best Practice Guidelines.



- For more details, see

Authors are expected to be aware of, and comply with, best practice in publication ethics specifically but not limited to, dual submission, plagiarism, manipulation of figures, competing interests, and compliance with policies on research ethics.

Reviewers and editors are required to treat manuscripts fairly and in confidence, and to declare competing interests.

TMT will investigate allegations of misconduct and will contact author institutions, funders or regulatory bodies, as needed.

TMT will follow COPE flowcharts and seek guidance as per COPE recommendations on resolving issues that may arise. Evidence of misconduct may require corrective action by issuing a correction or retraction.

Address concerns regarding misconduct to the journal’s Editors-in-Chief, Publisher, or Managing Editor, at We will address the issue with all appropriate person(s) as soon as possible, and send responses to confirm receipt of alleged misconduct.

Additional resources on publication ethics are available from COPEICMJE, and WAME.



Editorial Team


Telehealth and Medicine Today requires all board members and staff members to disclose relevant financial relationships.  An individual has a relevant financial relationship if he/she and/or a spouse or partner had a financial relationship in any amount occurring in the last 12 months with a commercial interest. 

All editorial and peer review board members may be asked to review manuscript submissions. TMT asks advisory and editorial board members to provide strategic input and participate in annual conference development, and/or moderate sessions. 






Lyle Berkowitz, MD, FACP, FHIMSS, CEO of Back9 Healthcare Consulting, USA

Focus area: Primary Care, Physician Satisfaction and Process innovation

Competing interests and/or financial disclosure

Board member at:


            Oneview Healthcare


Amar Gupta, PhD, MIT’s Institute of Medical Engineering and Science (IMES), Computer Science and Artificial Intelligence Labs (CSAIL) and Department of Electrical Engineering and Computer Science. USA

Focus area: Technology, Policy & Regulation

Competing interests and/or financial disclosure

  1. Served as Advisor to MITRE for Technical Exchange Meeting (TEM) involving US Federal Government, and paid as independent consultant
  2. Paid Keynote Address for Artificial Intelligence in Healthcare: The Role of Medical Boards. Paid for by McDermott Will & Emery LLP
  3. Consultant to Walmart Health for Telemedicine for Business Strategy, paid for by Walmart
  4. Lead researcher on Telemedicine Interactions and Face to Face Interactions in Critical Care Medicine and Other Clinical Specialties: Enhancing Effectiveness of Virtual Teams thru Systems Engineering” project sponsored by Philips at MIT and receiving funding as salary via MIT
  5. Consultant to United Technology Corporation on issues related to AI, not healthcare
  6. Part of proceed received for MIT Hacking Machine and King Abdulaziz City for Science and Technolog used to support Dr. Gupta's research and team at MIT.


John D. Halamka, MD, MS, President, Mayo Clinic Platform, USA

Focus area: Emergency and Hospital Medicine, Interoperability and Device Innovation

Competing interests and/or financial disclosure

  1. Arcadia Healthcare Solutions Advisory Board
  2. New Leaf Venture Partners Advisory Board
  3. Orion Healthcare Board of Directors
  4. Gates Foundation Consultant



Assistant Editors-in-Chief



Oren J. Mechanic, MD MPH, Instructor, Harvard Medical School, Attending Physician, Emergency Medicine, Beth Israel Deaconess Medical Center, Health Policy and Management Fellow, Harvard Medical Faculty Physicians, USA

Competing interests

I have no commercial interests to declare.

Brendan F. Smith, Principle Software Systems Engineer and Department Leader – Telemedicine, The MITRE Corporation, USA

Competing interests

I have no commercial interests to declare.



Advisory Board Members


Richard Anglin, President and CEO, telmedx, USA

Competing interests

I own telmedx and all associated patent applications.


Richard Bakalar, M.D.  Vice President, Chief Strategy Officer, ViTel Net, USA

Competing interests

I have no conflicts of interest to declare.


Rafael J. Grossmann, , MD, General Trauma Surgery, Minimally Invasive & Robotic Surgery, Surgical Critical Care, Northern Light Health, USA

Competing interests



David B. Nash, MD, MBA, Founding Dean Emeritus Dr. Raymond C. & Doris N. Grandon, Professor of Health Policy, Jefferson College of Population Health, USA

Competing interests

I am a frequent speaker. Proceeds go to Jefferson University


Robert Matthews, PhD., CEO of NudgeWorX, President of Synaural, USA

Competing interests

I have no commercial interests to declare.


Shayan Vyas, MD, MBA, FAAP, VP Quality and Innovations,  Teladoc Health, Associate Professor of Pediatrics, University of Central Florida College of Medicine, USA

Competing interests

I’m employed and own shares of Teladoc Health.


Chris Wasden, Head of Pharma, Happify Health, Managing Director, Digital Disruption Advisors, USA

Competing interests

Happify Health Advisor



Editorial Board Members


Bryan T. Arkwright, MHA, Director, SCP Consulting Services, Adjunct Faculty, Wake Forest University School of Law, Editorial Board, Telehealth and Medicine Today, and Co-Founder/Chief Research Officer, Cromford Health, USA

Competing interests

I have no commercial interests to declare.


Robyn Baek, PMP, Vice President, Analytics & Insights, SOC Telemed, USA

Competing interests

I am employed at SOC Telemed.


Jan Bruhans, PhD,  Faculty, Biomedical Engineering, Czech Technical University, Prague, and First Faculty of Medicine, Department of Anesthesiology and Intensive Care, Charles University, Prague, Czech Republic

Competing interests

I have no commercial interests to declare.


Andrew J. Butler, PhD, MBA, PT, FAPTA, FASAHP, Dean and Professor, School of Health Profession, University of Alabama at Birmingham (UAB), USA

Competing interests

I have no commercial interests to declare.


Suman De, MD, Head of Government Healthcare Solutions, Analytics, Infosys, USA

Competing interests

Employed with Infosys Public Services


Prabhakaran Dorairaj,, MD, DM (Cardiology), MSc, FRCP, FNASc, Vice President (Research and Policy), Director, Centre for Control of Chronic Conditions, Public Health Foundation of India, India

Competing interests

I have no commercial interests to declare.


Samer Ellahham, MD, Chief Quality Officer, Senior Cardiovascular Consultant, Cleveland Clinic, Sheikh Khalifa Medical City , UAE

Competing interests

I have no commercial interests to declare.


Charles Gabrial, Chief Science Officer, Analytics and Evaluation Division, Strategy, Planning and Functional Integration, Defense Health Agency (DHA), USA

Competing interests

I have no commercial interests to declare.


Krishnan GanapathyM Ch Neurosurgery, FACS, FICS, FAMS, PhD, Director, Apollo Telemedicine Networking Foundation, Director, Apollo Tele Health Services and Past President, Telemedicine Society of India, India

Competing interests

I have no commercial interests to declare.


Guy Glorioso, MHA, MBA, Vice President, Emerging Care Model Division and Virtual Health, Atrium Health, USA

Competing interests

I have no commercial interests to declare.


Francis L. McVeigh, Director, Army Virtual Health, Patient Care Integration, Fort Detrick, MD, USA

Competing interests

I have no commercial interests to declare.


Ralph Panos, MS, Professor, Chief of Medicine, UC Health Cincinnati VA Hospital, USA

Competing interests

I have no conflicts of interest to declare.


Joel Reich, M.D., FACEP, Health Tech Consultant/Graduate level Population Health, Healthcare Economics, & Health Care Leadership Instructor, USA

Competing interests

I have no conflicts of interest to declare.


Mahendra Singh, MD, Chief Digital Health Officer, Benovymed Healthcare Pvt Ltd., India

Competing interests

I have no conflicts of interest to declare.



Review Board Members


Shailendra Dandge, MD, Department of Pharmacology, MediCiti Institute of Medical Sciences, Hyderabad, Telangana, India,  Society for Health Allied Research & Education, India (SHARE INDIA), Hyderabad, Telangana, India

Competing interests

I have no conflicts of interest to declare.


Kunal Parikh, Product Manager, Trualta Inc., India

Competing interests

I have no conflicts of interest to declare.


Arnab Paul, CEO Patient Planet, India

Competing interests

I am board member and shareholder of Patient Planet.


Claude J. Pirtle, MD, Chief Medical Information Officer, West Tennessee Healthcare, USA

Competing interests

I have no conflicts of interest to declare.


Matthew Sakumoto, MD, Primary care physician and clinical informatics lead at Circle Medical, Assistant Clinical Professor at UCSF, USA

Competing interests

I am employed by Circle Medical.


Debbie Voyles, Executive Director, Virtual Health, UCHealth, Denver Colorado, USA

Competing interests

I am employed by UCHealth, Aurora, CO. I have received honoraria from Maine Health to present at their Telehealth Summit. I have received support to participate in Vidyo Telehealth Summit and Vidyo Telehealth Advisory Board in October 2017. Travel support to participate in InTouch Telehealth Summit in 2016. Travel support to present at Maine Health Summit about UCHealth rollout of Virtual Health. I have received funds to cover travel costs to attend vendor Summits to learn about their new Telehealth applications as well as honorarium to speak at the Maine Health Summit about how UCHealth has rolled out our Virtual Health program within the EPIC environment. Any funding I have received or will receive for travel costs from vendors will not influence my decision or affect my ability to choose the best software or hardware options for our Virtual Health program.


Haleema Yezdani, MBBS, FICM, General physician and teleconsultant, Cartula Health Care, India

Competing interests

I have no conflicts of interest to declare.


Stephanie Zawada, MS, Public Health Academy Instructor at the American Medical Students Association, USA

Competing interests

I have no conflicts of interest to declare.



Operations Management


Tory Cenaj, Founder, Owner, and Publisher, Partners in Digital Health, USA

Competing interests

I am the founder and owner of Partners in Digital Health, including the journals Blockchain in Healthcare Today, Telehealth and Medicine Today, all related activities and initiatives associated with these titles, and company portfolio. I volunteer for, and own, SolarCoin. I am advisor for IEEE-SA and NixWhistle.


John Russo Jr., PharmD, Managing Editor, Telehealth and Medicine Today, USA,

Competing interests

I am the owner of The MedCom Resource.



Telehealth and Medicine Today Alliance & Partnership Ambassador


Bryan T. Arkwright, MHA, Director, SCP Consulting Services, Adjunct Faculty, Wake Forest University School of Law, Editorial Board, Telehealth and Medicine Today, and Co-Founder/Chief Research Officer, Cromford Health, USA;

Competing interests
I have no commercial interests to declare.


Telehealth and Medicine Today Marketing & UX Strategy Advisor 

Ron Ribitzky MD, Founder & CEO of R&D Ribitzky, Boston, MA, USA

Competing interests

Stock shareholder of iSpecimen. Business Partner of, East-West Digital News, ACTIMIRA., and TALENTGRID VENTURES.  Strategic Advisor and token rights holder ARNA Genomics, BitMED. MarketsandMarkets Honorarium recipient.  Komodo Health


Collection Information